Based on interim safety findings from a pre-clinical, non-GLP pharmacology study, FDA has placed a clinical hold on the BMN 307 Phearless Phase 1/2 study, BioMarin Pharmaceutical Inc. (BMRN) said. The study is evaluating BMN 307, an investigational AAV5-phenylalanine hydroxylase gene therapy in adults with phenylketonuria.
The company carried out the pre-clinical study to understand the durability of BMN 307 activity in mice bearing two germline mutations. Of 63 animals treated, six of seven animals administered BMN 307 at the highest dose group had tumors on liver necropsy 52 weeks after dosing.
BioMarin said the clinical significance of these pre-clinical rodent findings has not been established. However, the company is pausing further enrollment into this global Phase 1/2 study until the investigation of these findings is completed.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.